How Are DNA Repair Systems Targeted in Cancer Therapy?
Targeting DNA repair pathways has become a promising strategy in cancer therapy. One such approach is the use of PARP inhibitors in cancers with defective homologous recombination, such as those with BRCA mutations. By inhibiting PARP, an enzyme involved in single-strand break repair, cancer cells with compromised HR are unable to repair DNA damage effectively, leading to cell death.
